GSK acquires Merck’s cancer immunotherapy for up to €3.7 billion

GlaxoSmithKline (GSK) and Merck have entered into a global strategic alliance to jointly develop and commercialise M7824, an investigational bifunctional fusion protein immunotherapy that is currently in clinical development, including potential registration studies, for multiple difficult-to-treat cancers. This includes a Phase II trial to investigate M7824 compared with pembrolizumab as a first-line treatment in patients … Continue reading GSK acquires Merck’s cancer immunotherapy for up to €3.7 billion